Drugs / CT1182
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07548697 | Apr 2026 → Dec 2028 expected | diffuse large B-cell lymphoma, follicular lymphoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT1182 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07548697 ↗ |
| Modality | Cell therapy | “in vivo car-t product (CT1182)” NCT07548697 ↗ |
| Route | Intravenous | “after intravenous infusion of lentivirus” NCT07548697 ↗ |
| Target | CD19 | “which simultaneously targets CD19 and CD20” NCT07548697 ↗ |